MFC.TO Stock Today: Q4 Beat, 10% Dividend Hike; U.S. Claims Weigh, February 13

Manulife stock fell today even after a Q4 earnings beat and a 10% dividend hike to C$0.49 per share. The move came as U.S. core earnings declined on unfavorable high‑net‑worth life claims. On the TSX, MFC.TO traded lower by more than 5%, putting fresh focus on valuation, dividend yield, and near‑term risks. We break down the print, today’s price action, and what Canadian investors should monitor from here, with clear numbers and practical takeaways.

Q4 beat and a 10% dividend hike

Manulife beat Q4 estimates, showing resilient core performance across businesses, while U.S. core earnings declined on unfavorable high‑net‑worth life claims. The company also raised its quarterly dividend by 10% to C$0.49, signaling confidence in cash generation. The mix of strong overall results and a targeted U.S. headwind shaped today’s reaction. Source: The Globe and Mail.

The new dividend of C$0.49 per quarter equals C$1.96 annualized. At today’s C$48.70 price, that implies a forward yield near 4.0%. The TTM dividend was C$1.76, for a 3.6% trailing yield. A payout ratio near 55% supports sustainability. For income seekers, the larger cash return offsets some price volatility and raises the floor for long‑term total returns.

Manulife stock today: price, valuation and technicals

Manulife stock slipped 5.25% to C$48.70, down C$2.70, on elevated volume of 10,871,024 shares versus a 5,983,109 average. The session ranged between C$48.48 and C$51.74 after a C$51.27 open. The 52‑week range stands at C$36.93 to C$52.97. Short‑term performance cooled, but the six‑month gain remains 17.28%, showing solid medium‑term momentum.

At today’s price, the P/E is 15.61 on EPS of C$3.12. The price‑to‑book is about 1.61 on book value per share of C$31.24. Return on equity is 11.5%. Meyka Stock Grade is 76.38 (B+), suggesting BUY, while our Company Rating reads B with a Neutral tilt due to mixed factor scores across ROA, P/E, and PB.

Technicals show an RSI near 69, ADX at 30.55, and a positive MACD histogram. Price tested the Bollinger lower band at C$48.20, with an upper band near C$51.82. ATR of 0.74 points to active swings. Momentum cooled after recent strength, so entries may favor staged buys and strict risk limits while volatility remains elevated.

U.S. claims trim sentiment despite Q4 strength

Management flagged weaker U.S. core earnings due to unfavorable claims in high‑net‑worth life policies. Investors often treat such claim spikes as episodic, but today’s miss in that segment pressured the multiple. The market weighed this near‑term drag against a broader Q4 beat and the dividend raise. Source: The Globe and Mail.

Broader Canadian life insurers posted healthy results, suggesting industry fundamentals remain sound. Sun Life reported stronger Q4 profit growth, reinforcing sector resilience even as company‑specific issues surfaced at Manulife. This context supports a balanced view on the group while we track Manulife’s U.S. claim trends. Source: CP24.

What to watch from here

The higher dividend lifts income appeal, while diversified earnings from Asia, Canada, and Wealth and Asset Management provide balance to U.S. insurance swings. Watch sales trends in asset management, lapse rates, and expense control. If core growth holds and claims normalize, Manulife stock can re‑rate toward prior highs while paying investors to wait.

Next earnings are scheduled for May 5, 2026. Key watch items include U.S. claim severity and frequency, interest rate paths that affect spreads, equity market levels for fee income, and capital deployment priorities. Track valuation versus peers, book value growth, and dividend coverage. Clear improvement on U.S. claims would be the fastest way to repair sentiment.

Final Thoughts

Manulife stock delivered a clear mix today: a Q4 earnings beat and a 10% dividend hike to C$0.49 signal strong capital return, while weaker U.S. core earnings on high‑net‑worth life claims pressured the share price. On the TSX, the drop to C$48.70 lifted the forward yield to about 4.0%, with a payout near 55%. Valuation sits at 15.61 times earnings and roughly 1.61 times book, near historical mid‑range levels. For Canadian investors, the setup looks balanced. Income investors get a bigger cheque, and long‑term holders can watch for U.S. claim normalization. Consider phased entries, respect volatility, and reassess after next quarter’s update on claims and cash generation.

FAQs

Why did Manulife stock fall after a Q4 earnings beat?

Shares slid because U.S. core earnings declined on unfavorable high‑net‑worth life claims, which offset the broader beat. The market priced a near‑term drag on profitability and kept the multiple in check despite a stronger dividend and resilient performance in other regions.

What is the new dividend and implied yield for Manulife?

The quarterly dividend rose 10% to C$0.49, or C$1.96 annualized. At today’s C$48.70 price, that implies a forward yield near 4.0%. The trailing 12‑month dividend was C$1.76, for a 3.6% trailing yield. Coverage looks reasonable with a payout near 55%.

Is Manulife stock attractive for income investors now?

The higher dividend improves income appeal, and the forward yield near 4.0% is competitive in Canada. If U.S. claims normalize, total returns can improve. Consider averaging in and watching coverage metrics, book value growth, and management commentary on claims trends next quarter.

What key dates should investors watch next?

Mark May 5, 2026 for the next earnings release. Ahead of that, track monthly market moves, interest rate signals, and any management updates on U.S. claim severity. Price action near C$48 to C$52, plus dividend coverage metrics, will guide risk and potential re‑rating.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.